Novasign
Novasign is a Vienna-based SaaS company offering bioprocess modeling and digital twin software that combines mechanistic and data-driven hybrid modeling to accelerate process development for CDMOs, biopharmaceutical companies, and industrial biotech producers.
- Company typePrivate
- Founded2019
- HeadquartersVienna, Austria
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Novasign does
Novasign GmbH is a Vienna-based software company founded in 2019 that develops Novasign Studio, a bioprocess modeling and digital twin platform aimed at accelerating development and scale-up for biopharmaceutical and industrial biotechnology processes. The company's core technology is hybrid modeling, which combines mechanistic first-principles process understanding with data-driven machine learning to create explainable workflows for experiment design, data preprocessing, model building, and simulation. Studio integrates two modules — a Hybrid Modeling Toolbox and a Digital Twin environment — and supports both no-code interfaces for process engineers and code extensibility through an embedded Visual Studio Code environment. Deployment options include cloud-based SaaS and fully on-premises installations to meet stricter data requirements in pharmaceutical manufacturing.
The platform is distributed through a hybrid go-to-market combining product-led growth (a downloadable freemium version of Studio) with enterprise field sales (personalized demo calls, guided pilot programs, and tailored workshops). Revenue streams include recurring software subscriptions, professional services for bioprocess modeling consulting and process development, and training services. Primary customer segments are CDMOs and large biopharma companies, with secondary segments in industrial biotech and continuous biomanufacturing; named enterprise relationships include Roche, Takeda, Lonza, Repligen, Siemens, and SimVantage.
The company originated from a 2016 research consortium funded by the Austrian Research Promotion Agency (FFG) with €1.6 million, involving the University of Natural Resources and Life Sciences Vienna, the University of Lisbon, and the University of Newcastle. In August 2025, Novasign entered a strategic partnership with Repligen Corporation, which included a corporate investment and integration of Novasign's modeling technology into Repligen's filtration systems. The company is led by Managing Director Dipl.-Ing. Dr. Mark Dürkop and operates as a privately held Gesellschaft mit beschränkter Haftung (GmbH) registered in Vienna.
Novasign firmographics
Firmographics- Name
- Novasign
- Legal name
- Novasign GmbH
- Website
- https://novasign.at
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Novasign is a Vienna-based SaaS company offering bioprocess modeling and digital twin software that combines mechanistic and data-driven hybrid modeling to accelerate process development for CDMOs, biopharmaceutical companies, and industrial biotech producers.
- Ownership category
- akta.pro rank
Novasign industry classification
Industry- Product category
- Bioprocess Modeling Software
- NAICS
- Computer Systems Design Services (541512)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- Digital Twins & Scenario-Based Systems Training (Equipment/Process Simulators) (EDAFAJAJ)
Keywords
Where Novasign is headquartered
LocationHeadquarters
- HQ city
- Vienna
- HQ country
- Austria
- HQ region
- Europe
Offices1 record
Markets served
Novasign business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations
Revenue model
- Software Licensing (Novasign Studio): SaaS-style subscription access to the Novasign Studio platform available in cloud-based or fully on-premises deployment. Customers can access Studio independently or through guided pilot programs with expert support.
- Professional Services - Consulting: Bioprocess modeling consulting services where Novasign experts develop modeling workflows on customer data, run tests, and deliver tailored solutions.
- Software Training: Training services including workshops on standard datasets and tailored workshops for guided pilots, helping teams learn to use Studio independently.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Others | Freemium Access |
| Subscription | Monthly | Studio Access (Self-Service) |
| Subscription | Annual | Guided Pilot |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels8 records
Novasign product offering
Product offeringCore offering
Novasign develops Novasign Studio, a bioprocess modeling and digital twin software platform available cloud-based or fully on-premises. The platform combines mechanistic first-principles process understanding with data-driven machine learning in hybrid modeling workflows, connecting experimental design, data preprocessing, model building, and simulation for bioprocess development, scale-up, and manufacturing. It serves CDMOs, biopharma, and industrial biotech firms with reusable process workflows that reduce experimental effort.
Product overview
Novasign offers Novasign Studio as its core unified product platform for bioprocess modeling, simulation, and decision support. The platform includes two integrated modules: the Hybrid Modeling Toolbox for combining mechanistic and data-driven approaches, and the Digital Twin for virtual process replication and autonomous optimization. Services include bioprocess modeling consulting, process development, and software training. Novasign serves CDMOs, Biopharma, and Industrial Biotech sectors.
Differentiator
Problem solved
Functional benefit
Brands
- Novasign Studio: Bioprocess Modeling and Digital Twin Software that turns fragmented experiments and process data into explainable workflows for bioprocess modeling, simulation, and decision support.
- Hybrid Modeling Toolbox
- Digital Twin
Products and services
- Novasign Studio Cloud-based or on-premises bioprocess modeling and digital twin software that turns fragmented experiments and process data into explainable workflows for bioprocess modeling, simulation, and decision support from development to manufacturing. Supports no-code for process engineers with code extensibility via embedded Visual Studio Code for data scientists.
- Bioprocess Modeling Services Consulting services in which Novasign bioprocess experts develop modeling workflows on customer data, run tests, and deliver tailored modeling solutions for CDMOs, biopharma, and industrial biotech clients.
- Process Development Services Expert-guided process development services including guided pilots and tailored workshops helping customer teams build, validate, and reuse bioprocess modeling workflows.
- Software Training Services Training services including workshops on standard datasets and tailored workshops for guided pilots, helping teams learn to use Novasign Studio independently.
Quantifiable outcome
- Reduced experimental runs from 22 to 8, cutting material costs by ~€40k and accelerating development by 12 weeks
- +4 more outcomes
Companies that use Novasign
Customer profileNamed customers6 records
Segments4 records
Ideal customer profiles3 records
Novasign technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability6 records
Feature6 records
Novasign partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core, strategic and minor.
- Repligen CorporationcoreStrategic partnership to develop AI-driven digital solutions for bioprocessing, with Repligen investing in Novasign. Collaboration aims to integrate Novasign's modeling technology into Repligen's filtration systems to enhance digitalization, reduce development time, and enable predictive control. Repligen is a leading life sciences company providing products to biopharmaceutical companies worldwide.
- TakedacoreCollaboration between Takeda and Novasign to investigate applicability of PTR-MS (proton-transfer-reaction mass spectrometry) for HEK cultivations in gene therapy processes. Takeda provided gene therapy process expertise while Novasign contributed data evaluation and hybrid modeling capabilities to develop real-time soft sensors for monitoring and control.
- SiemenscoreCollaboration to implement Novasign's hybrid models in Siemens PAT Software Simatic SIPAT for real-time process monitoring and soft sensing in pharmaceutical manufacturing. Siemens LivingLab provided industrial environment for proof-of-concept implementation of biomass monitoring soft sensors.
- SimVantagecoreFive-year collaboration developing integrated modeling framework combining Novasign's biological process modeling with SimVantage's rapid-response reactor physics simulations for predictive scale-up across reactor scales and geometries.
- AntleroncoreJoint development of advanced process modeling strategies for ATMP (Advanced Therapy Medicinal Products) manufacturing. Collaboration focuses on model-based process optimization for adherent cell manufacturing processes, combining risk-based development, mDoE, soft-sensing, and hybrid modeling with Computational Fluid Dynamics.
- QubiconstrategicPartnership to enable faster implementation of Industry 4.0 concepts. Qubicon provides data management and contextualization platform while Novasign builds hybrid models. Seamless export enables model creation without manual data consolidation, supporting automated process control.
- Bilfinger AGminorCollaboration investigating transferability of process knowledge from shake flask hybrid models to 15L bioreactor scale within the same design space, demonstrating applicability of iDoE for mammalian bioprocesses.
- enGenes BiotechcoreECONTI project consortium for autonomous continuous biomanufacturing. enGenes provides microbial expression systems and continuous upstream processing. Developed integrated production chain for recombinant protein A production in E. coli combining upstream, filtration, and chromatography.
- Tosoh BiosciencecoreECONTI project consortium for autonomous continuous biomanufacturing. Tosoh provides continuous chromatography capabilities for the integrated production platform.
- BOKU (University of Natural Resources and Life Sciences, Vienna)coreECONTI project consortium contributing process development and downstream processing expertise for autonomous continuous biomanufacturing platform.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
Novasign competitors and assessment
Company assessmentDirect peers
- Insilico Biotechnology: Stuttgart-based provider of mechanistic and data-driven modeling software for bioprocess optimization (e.g., INSILICO platform). Closest direct competitor to Novasign in bioprocess hybrid modeling with an overlapping customer base in CDMOs and Big Pharma.
- Process Systems Enterprise (PSE): Provider of gPROMS process modeling platform used across chemicals, pharma, and bioprocessing for first-principles and hybrid model development. Direct peer in the process modeling / digital twin category with deeper footprint in traditional process industries.
Broad incumbents
- Siemens Process Industries (SIPAT): Siemens' PAT software platform for pharma manufacturing that Novasign integrates with via Simatic SIPAT. Broader incumbent with much larger installed base across pharmaceutical manufacturing and a multi-vendor automation portfolio.
- Sartorius: Global bioprocess solutions provider (upstream, downstream, automation, PAT). A large incumbent whose bioprocess automation portfolio overlaps with Novasign's customers and could increasingly bundle process modeling/Digital Twin capabilities.
- Cytiva: Major bioprocess hardware, single-use, and software provider (formerly GE Healthcare Life Sciences). Serves the same CDMO and Big Pharma customers with broader process development offerings and is a plausible consolidator of digital bioprocessing tools.
- Genedata: Provider of enterprise scientific software for biopharma R&D and bioprocess development. Targets similar biopharma customers with broader data management, screening, and process analytics software rather than focused hybrid modeling.
- BIOVIA (Dassault Systèmes): Scientific informatics portfolio (BIOVIA) covering lab informatics, process modeling, and simulation across life sciences. A broad incumbent with deeper manufacturing footprint and enterprise software stack that overlaps with Novasign's buyer personas.
Emerging players
- TetraScience: Biopharma-focused data cloud and AI platform sitting between instruments (including bioreactors) and analytics. Competes for the same customer's digital bioprocessing budget with a data infrastructure rather than hybrid-modeling approach.
- Benchling: Cloud R&D platform widely adopted in biopharma for molecule, process, and experimental data management. Competes for bioprocess development software budget; less focused on mechanistic/process modeling but increasingly adding analytical capabilities.
Others
- Repligen Corporation: Strategic investor and bioprocess filtration/analytics vendor that Novasign's modeling is being integrated into. Listed as a peer because of the deep commercial and technical coupling — and to acknowledge Repligen's emerging ability to either bundle or compete with bioprocess modeling capability.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Novasign social profiles
Digital presenceNovasign financial estimates
Financial estimateRevenue estimate
Valuation estimate
Novasign leadership team
Management profileNumber of profiles
Profiles1 record
Novasign funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Novasign M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Novasign
What does Novasign do?
Novasign develops Novasign Studio, a bioprocess modeling and digital twin software platform available cloud-based or fully on-premises. The platform combines mechanistic first-principles process understanding with data-driven machine learning in hybrid modeling workflows, connecting experimental design, data preprocessing, model building, and simulation for bioprocess development, scale-up, and manufacturing. It serves CDMOs, biopharma, and industrial biotech firms with reusable process workflows that reduce experimental effort.
Is Novasign a public or private company?
Novasign is a private company. It is classified as venture growth investor backed and is currently operating.
When was Novasign founded?
Novasign was founded in 2019. It employs 11 to 50 people.
Where is Novasign based?
Novasign is headquartered in Vienna, Austria, in the Europe region.
How does Novasign make money?
Three revenue lines are on record. Software Licensing (Novasign Studio) is the primary driver. The others are professional Services - Consulting and software Training.
Who are Novasign's main competitors?
Direct peers on record are Insilico Biotechnology and Process Systems Enterprise (PSE). Broad incumbents are Siemens Process Industries (SIPAT), Sartorius, Cytiva, Genedata and BIOVIA (Dassault Systèmes). Emerging players are TetraScience and Benchling. Repligen Corporation is listed as an others.
Does Novasign have an API?
Yes. Novasign Studio is described as 'API-ready integrations plus support for custom code and models', indicating API availability for integrations with external systems.
What industry is Novasign in?
Novasign's product category is Bioprocess Modeling Software. Its primary akta.pro industry code is EDAFAJAJ, Digital Twins & Scenario-Based Systems Training (Equipment/Process Simulators). Its NAICS code is 541512 and its SIC code is 7372.